<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0004808'>Acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) has a poor prognosis due to treatment-resistant relapses </plain></SENT>
<SENT sid="1" pm="."><plain>A humanized anti-CD33 antibody (Mylotarg) showed a limited response rate in relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>To discover novel <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> antibody targets, we selected a panel of single chain Fv fragments using phage display technology combined with flow cytometry on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples </plain></SENT>
<SENT sid="3" pm="."><plain>One selected single chain Fv fragment broadly reacted with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> samples and with myeloid cell lineages within peripheral blood </plain></SENT>
<SENT sid="4" pm="."><plain>Expression cloning identified the antigen recognized as C-type lectin-like molecule-1 (CLL-1), a previously undescribed transmembrane <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>CLL-1 expression was analyzed with a human anti-CLL-1 antibody that was generated from the single chain Fv fragment </plain></SENT>
<SENT sid="6" pm="."><plain>CLL-1 is restricted to the hematopoietic lineage, in particular to myeloid cells present in peripheral blood and bone marrow </plain></SENT>
<SENT sid="7" pm="."><plain>CLL-1 is absent on uncommitted CD34(+)/CD38(-) or CD34(+)/CD33(-) stem cells and present on subsets of CD34(+)/CD38(+) or CD34(+)/CD33(+) progenitor cells </plain></SENT>
<SENT sid="8" pm="."><plain>CLL-1 is not expressed in any other tissue </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, analysis of primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e> demonstrated CLL-1 expression in 92% (68 of 74) of the samples </plain></SENT>
<SENT sid="10" pm="."><plain>As an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> marker, CLL-1 was able to complement CD33, because 67% (8 of 12) of the CD33(-) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e> expressed CLL-1 </plain></SENT>
<SENT sid="11" pm="."><plain>CLL-1 showed variable expression (10-60%) in CD34(+) cells in <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> but was absent in 12 of 13 cases of <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> reactivity combined with the restricted expression on <z:mpath ids='MPATH_458'>normal</z:mpath> cells identifies CLL-1 as a novel potential target for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> treatment </plain></SENT>
</text></document>